143 related articles for article (PubMed ID: 18757786)
21. Chronopharmacology of roflumilast: a comparative pharmacokinetic study of morning versus evening administration in healthy adults.
Bethke TD; Huennemeyer A; Lahu G; Lemmer B
Chronobiol Int; 2010 Oct; 27(9-10):1843-53. PubMed ID: 20969527
[TBL] [Abstract][Full Text] [Related]
22. Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects.
Abbas R; Leister C; El Gaaloul M; Chalon S; Sonnichsen D
Clin Ther; 2012 Sep; 34(9):2011-9.e1. PubMed ID: 22884766
[TBL] [Abstract][Full Text] [Related]
23. The pharmacokinetics of darexaban (YM150), an oral direct factor Xa inhibitor, are not affected by ketoconazole, a strong inhibitor of CYP3A and P-glycoprotein.
Groenendaal D; Strabach G; Garcia-Hernandez A; Kadokura T; Heeringa M; Mol R; Eltink C; Onkels H
Clin Pharmacol Drug Dev; 2014 May; 3(3):194-201. PubMed ID: 27128609
[TBL] [Abstract][Full Text] [Related]
24. Single-dose pharmacokinetics of roflumilast in children and adolescents.
Neville KA; Szefler SJ; Abdel-Rahman SM; Lahu G; Zech K; Herzog R; Bethke TD; Gleason MC; Kearns GL
J Clin Pharmacol; 2008 Aug; 48(8):978-85. PubMed ID: 18508947
[TBL] [Abstract][Full Text] [Related]
25. High absolute bioavailability of the new oral phosphodiesterase-4 inhibitor roflumilast.
Bethke TD; Lahu G
Int J Clin Pharmacol Ther; 2011 Jan; 49(1):51-7. PubMed ID: 21176727
[TBL] [Abstract][Full Text] [Related]
26. A single-center, open-label, one-sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib.
Derks M; Fowler S; Kuhlmann O
Clin Ther; 2009 Mar; 31(3):586-99. PubMed ID: 19393849
[TBL] [Abstract][Full Text] [Related]
27. Roflumilast Cream Improves Signs and Symptoms of Plaque Psoriasis: Results from a Phase 1/2a Randomized, Controlled Study.
Papp KA; Gooderham M; Droege M; Merritt C; Osborne DW; Berk DR; Thurston AW; Smith VH; Welgus H
J Drugs Dermatol; 2020 Aug; 19(8):734-740. PubMed ID: 32845114
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic evaluation of roflumilast.
Lahu G; Nassr N; Hünnemeyer A
Expert Opin Drug Metab Toxicol; 2011 Dec; 7(12):1577-91. PubMed ID: 22059647
[TBL] [Abstract][Full Text] [Related]
29. Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects.
Abbas R; Hug BA; Leister C; Burns J; Sonnichsen D
J Clin Pharmacol; 2011 Dec; 51(12):1721-7. PubMed ID: 21148045
[TBL] [Abstract][Full Text] [Related]
30. Study investigating pharmacokinetic interaction between theophylline and roflumilast in healthy adults.
Böhmer G; Gleiter CH; Hünnemeyer A; Lahu G; Bethke TD
Int J Clin Pharmacol Ther; 2011 Jul; 49(7):451-60. PubMed ID: 21726496
[TBL] [Abstract][Full Text] [Related]
31. Simultaneous determination of roflumilast and its metabolite in human plasma by LC-MS/MS: Application for a pharmacokinetic study.
Cui X; Huang J; Zheng X; Jiang J; Kuang Y; Hu P
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Sep; 1029-1030():60-67. PubMed ID: 27423044
[TBL] [Abstract][Full Text] [Related]
32. Effect of ketoconazole on the pharmacokinetic profile of ambrisentan.
Richards DB; Walker GA; Mandagere A; Magee MH; Henderson LS
J Clin Pharmacol; 2009 Jun; 49(6):719-24. PubMed ID: 19389876
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of Cytochrome P450 (CYP) 3A4-Based Interactions of Levomilnacipran with Ketoconazole, Carbamazepine or Alprazolam in Healthy Subjects.
Chen L; Boinpally R; Gad N; Greenberg WM; Wangsa J; Periclou A; Ghahramani P
Clin Drug Investig; 2015 Oct; 35(10):601-12. PubMed ID: 26315684
[TBL] [Abstract][Full Text] [Related]
34. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
[TBL] [Abstract][Full Text] [Related]
35. Magnesium hydroxide/aluminium hydroxide-containing antacid does not affect the pharmacokinetics of the targeted phosphodiesterase 4 inhibitor roflumilast.
Nassr N; Lahu G; Hünnemeyer A; von Richter O; Knoerzer D; Reutter F; Zech K; Hermann R
J Clin Pharmacol; 2007 May; 47(5):660-6. PubMed ID: 17374735
[No Abstract] [Full Text] [Related]
36. A Nonhuman Primate PET Study: Measurement of Brain PDE4 Occupancy by Roflumilast Using (R)-[
Takano A; Uz T; Garcia-Segovia J; Tsai M; Lahu G; Amini N; Nakao R; Jia Z; Halldin C
Mol Imaging Biol; 2018 Aug; 20(4):615-622. PubMed ID: 29441434
[TBL] [Abstract][Full Text] [Related]
37. The PDE4 inhibitor roflumilast improves memory in rodents at non-emetic doses.
Vanmierlo T; Creemers P; Akkerman S; van Duinen M; Sambeth A; De Vry J; Uz T; Blokland A; Prickaerts J
Behav Brain Res; 2016 Apr; 303():26-33. PubMed ID: 26794595
[TBL] [Abstract][Full Text] [Related]
38. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions.
van Schalkwyk E; Strydom K; Williams Z; Venter L; Leichtl S; Schmid-Wirlitsch C; Bredenbröker D; Bardin PG
J Allergy Clin Immunol; 2005 Aug; 116(2):292-8. PubMed ID: 16083782
[TBL] [Abstract][Full Text] [Related]
39. Sensitive quantification of roflumilast and roflumilast N-oxide in human plasma by LC-MS/MS employing parallel chromatography and electrospray ionisation.
Knebel NG; Herzog R; Reutter F; Zech K
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Apr; 893-894():82-91. PubMed ID: 22425388
[TBL] [Abstract][Full Text] [Related]
40. Roflumilast for the treatment of chronic obstructive pulmonary disease.
Rabe KF
Expert Rev Respir Med; 2010 Oct; 4(5):543-55. PubMed ID: 20649375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
